Mainz Biomed NV
F:4TO
Mainz Biomed NV
Inventory
Mainz Biomed NV
Inventory Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Inventory | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Mainz Biomed NV
F:4TO
|
Inventory
$372.9k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
BioNTech SE
NASDAQ:BNTX
|
Inventory
€283.3m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
88%
|
CAGR 10-Years
N/A
|
|
|
CureVac NV
NASDAQ:CVAC
|
Inventory
€541k
|
CAGR 3-Years
-79%
|
CAGR 5-Years
-39%
|
CAGR 10-Years
N/A
|
|
|
Immatics NV
NASDAQ:IMTX
|
Inventory
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Biotest AG
XETRA:BIO
|
Inventory
€523.7m
|
CAGR 3-Years
27%
|
CAGR 5-Years
11%
|
CAGR 10-Years
8%
|
|
|
Formycon AG
XETRA:FYB
|
Inventory
€262k
|
CAGR 3-Years
8%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-3%
|
|
Mainz Biomed NV
Glance View
Mainz Biomed NV is a molecular genetics cancer diagnostic company. The company is headquartered in Mainz, Hessen and currently employs 58 full-time employees. The company went IPO on 2021-11-04. The firm operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The firm competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.
See Also
What is Mainz Biomed NV's Inventory?
Inventory
372.9k
USD
Based on the financial report for Dec 31, 2024, Mainz Biomed NV's Inventory amounts to 372.9k USD.
What is Mainz Biomed NV's Inventory growth rate?
Inventory CAGR 1Y
-39%
Over the last year, the Inventory growth was -39%.
